Key statistics
As of last trade, Akero Therapeutics Inc (0K4:DEU) traded at 25.74, 142.83% above the 52 week low of 10.60 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.87 |
---|---|
High | 26.03 |
Low | 24.87 |
Bid | 25.49 |
Offer | -- |
Previous close | 25.44 |
Average volume | 162.63 |
---|---|
Shares outstanding | 69.43m |
Free float | 58.95m |
P/E (TTM) | -- |
Market cap | 1.96bn USD |
EPS (TTM) | -3.41 USD |
Data delayed at least 15 minutes, as of Oct 04 2024.
More ▼
- Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
- Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
- Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
- Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
- Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
- Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
- Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
More ▼